iMineIVF
醫藥
USD 2.99 · 專為 iPad 設計。尚未針對 macOS 驗證。
iMineIVF v.5 patient app now provides fertility clinics a complete suite of functionalities aimed at exchanging live instructions, communications and admission tickets with their patients while in treatment.
Navigation includes:
- Clinic credentials (Clinic ID + 3-letters identifier) issued at admissions
- Published cycle instructions, prescriptions + video tutorials
- Health reports + personalized documents
- Boarding passes for upcoming confirmed appointments + steps to follow
- In-cycle inquiries + Q&A chats
At 1st login, patients:
- Securely use clinic-provided credentials + DOB
At subsequent logins, patients:
- Personalize passwords with 2-factor authentication
- Activate biometrics (optional)
At check-in kiosks:
- Scan boarding passes for sign-ins + locations directory
When in treatment:
- Review daily instructions + medications
- Check upcoming appointments
- Sync select items to phone calendar (optional)
- Preview shared video tutorials
- Redirect docs + reports on choice platforms (optional)
- Chat with clinic staff for Q&A inquiries
- Call the clinic emergency number (optional)
- Add appointments to Wallet (optional)
iMineIVF content is actively updated by the clinic, notifying patients of any changes made to their treatments, as these occur.
Our team wishes you a successful IVF attempt.
評分與評論
- 此App未收到足夠的評分或評論以顯示概況。
- Updated + enhanced login functionalities
- Patient appointments suite
- Push notifications for any treatment updates
- Revised documents management
- Danish language support
- Minor bug fixes + optimization
開發者BabySentry Ltd.表明App的私隱慣例或包括下列資料的處理。詳情請參閲 開發者的私隱政策 。
不收集資料
開發者不會從此 App 收集任何資料。
輔助使用
開發者尚未表示此 App 支援哪些輔助使用功能。 進一步了解
資料
- 供應商
- BabySentry Ltd.
- 大小
- 7.1 MB
- 類別
- 醫藥
- 相容性
須使用 iOS 15.6 或以上版本。
- iPhone
須使用 iOS 15.6 或以上版本。 - iPad
須使用 iPadOS 15.6 或以上版本。 - iPod touch
須使用 iOS 15.6 或以上版本。 - Mac
須使用 macOS 12.5 或以上版本及配備 Apple M1 或以上版本晶片的 Mac。 - Apple Vision
須使用 visionOS 1.0 或以上版本。
- iPhone
- 語言
- 英文
- 年齡分級
16+
- 16+
- 頻繁
醫療資訊
- 版權
- © BabySentry Ltd. 2025
